RE: RNS19 Dec 2023 07:06
London, 19 December 2023, Hellenic Dynamics Plc (LSE: HELD), a medical cannabis cultivator with a dedicated focus on producing tetrahydrocannabinol ("THC") dominant strains of medical cannabis flowers for the fast growing European medical cannabis markets, announces that it has entered into a five year memorandum of understanding ("MOU") with The University of Patras, Greece.
Under the terms of the MOU, the Company and the Laboratory of Molecular Pharmacology, Department of Pharmacy of The University of Patras intends to enter into and collaborate to develop joint scientific research projects. It is Hellenic Dynamics' intention that the collaborative projects will focus on cannabis-based molecules to be used for clinical trials with a view to cultivate plants to be used by large pharmaceutical companies.
The Laboratory of Molecular Pharmacology is headed by Professor Evangelia Papadimitriou who among other roles has served as Chairman of the Committee for listing reimbursed medicinal products in Greece and has been a member of various committees, including the Hellenic Central Board of Health (Ministry of Health), in medicine-related matters. Evangelia is also served as a member of the Hellenic Society of Basic and Clinical Pharmacology.
The primary areas of research of the Laboratory of Molecular Pharmacology, headed by Professor Papadimitriou Evangeli, are focused on pharmacological mechanisms that can be potentially targeted therapeutically, and play a role in the pathophysiology of both endothelial cells and smooth muscle cells of the arterial wall, as well as in physiological and cancer angiogenesis, specifically tumour growth and anti-tumour activity.
Davinder Rai, CEO of Hellenic Dynamics, commented: "The Laboratory of Molecular Pharmacology at The University of Patras is well known for its advanced research into cancer and into medical cannabis. This five year agreement allows Hellenic Dynamics and its partners the opportunity to work with The University of Patras on the advancement of cannabis-based molecules through various stages of clinical trials with shared data.